Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Medicines in Devlopment for Cancer, 2008  
  • Thousands of potential cancer medicines in development
     
  • Death rates from breast cancer declined by an average of 2.3% per year between 1990 and 2002 because of earlier detection through screening, better awareness, and improved treatments.  
  • Studies have shown that annual mammograms reduce breast cancer related mortality in women by 20-40%.  
  • The Impact of Personalized Medicine on Cancer Survival in Years